Mice that produced the peptide showed weaker long-term memory formation and fewer PTSD-like behaviors after a traumatic-memory test.
Researchers studied QBP1, a peptide that blocks the self-assembly of CPEB3, a protein involved in forming long-term memories. In laboratory tests, the active part of QBP1 inhibited the amyloid form of human CPEB3 without affecting another process called phase separation.
The team then created mice that continuously produced QBP1. These mice had weaker consolidation of simple and aversive memories after 24 hours, while their short-term memory was unchanged. In a PTSD-like experiment, they showed more extinction of the traumatic memory and less anhedonia than control mice. The findings support further testing of CPEB3 blocking in pharmacological or post-developmental models.
How the peptide changed memory
In test-tube experiments, the active core of QBP1, called QBP1-M8, inhibited the amyloid aggregation of human CPEB3 without affecting its phase separation. The researchers then generated transgenic mice that continuously expressed QBP1.
After 24 hours, these mice showed impaired consolidation of simple learning, including both hippocampus-dependent and aversive memories. Their short-term memory was not affected. In a fear-context test, recall was reduced and the animals did not show the expected extinction pattern. Under a separate PTSD-like protocol, however, the QBP1 mice showed significant extinction of the traumatic memory and reduced anhedonia compared with control mice, which showed persistent aversive memory and anhedonia.
Analysis of hippocampal samples also found a correlative decrease in the oligomerization, or formation of larger protein assemblies, of mouse CPEB3 in the QBP1 mice.
// Source
Advanced Science · 2026 · DOI: 10.1002/advs.202502541
Authors: Paula López-García, Kerry R. McGreevy, María Eugenia Vaquero, Juan M. Suarez‐Rivero, Antonio Moreno-Rodríguez, Antonio J. Pérez‐Pulido, Daniel Ramírez de Mingo, Anna Pallé, H. Akiko Popiel, Andrea Santi, Mario David Cordero, José Luís Trejo, Yoshitaka Nagai, Mariano Carrión‐Vázquez
Institutions: Johns Hopkins University, The University of Osaka, Osaka Gakuin University, Kindai University Sakai Hospital, Saitama International Medical Center, Kindai University, Tokyo Medical University, Salk Institute for Biological Studies, Instituto Cajal, Universidad Pablo de Olavide, National Center of Neurology and Psychiatry